

L-267

References

1. Berger BM, Hanna GJ, Posner MR, et al. Detection of occult recurrence using circulating tumor tissue modified viral HPV DNA among patients treated for HPV-driven oropharyngeal carcinoma. *Clin Cancer Res*. 2022;28(19):4292-4301.
2. Chera BS, Kumar S, Beaty BT, et al. Rapid clearance profile of plasma circulating tumor HPV type 16 DNA during chemoradiotherapy correlates with disease control in HPV-associated oropharyngeal cancer. *Clin Cancer Res*. 2019;25(15):4682-4690
3. Chera BS, Kumar S, Shen C, et al. Plasma circulating tumor HPV DNA for the surveillance of cancer recurrence in HPV-associated oropharyngeal cancer. *J Clin Oncol*. 2020;38(10):1050-1058.
4. Gunning A, Kumar S, Williams CK, et al. Analytical validation of NavDx, a cfDNA-Based fragmentomic profiling assay for HPV-driven cancers. *Diagnostics (Basel)*. 2023;13(4):725.
5. Misawa K, Imai A, Matsui H, et al. Identification of novel methylation markers in HPV-associated oropharyngeal cancer: Genome-wide discovery, tissue verification and validation testing in ctDNA. *Oncogene*. 2020;39(24):4741-4755.
6. Rettig EM, Wang AA, Tran N-A, et al. Association of pretreatment circulating tumor tissue-modified viral HPV DNA with clinicopathologic factors in HPV-positive oropharyngeal cancer. *JAMA Otolaryngol Head Neck Surg*. 2022;148(12):1120-1130.